Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Efficacy Results Across Study Indications:

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.